Abstract Details

Title Frequency of Neuromyelitis Optica Spectrum Disorder Correlated Symptoms: A Pre- and Post-diagnosis Comparison from a National Dataset

Topic Autoimmune Neurology

Presentation(s) P10 - Poster Session 10 (11:45 AM-12:45 PM)

Poster/Presentation
Number 14-011

Objective

Determine most common symptom diagnoses of neuromyelitis optica spectrum disease (NMOSD) pre- and post-NMOSD diagnosis and how the symptoms are followed.

Background

NMOSD is an antibody-mediated autoimmune disorder affecting the central nervous system, mainly targeting the optic nerves and spinal cord. Common clinical characteristics of NMOSD include myelitis, optic neuritis, neurogenic pain, nausea/vomiting/hiccups, fatigue, and bowel/bladder dysfunction.

Design/Methods

NMOSD diagnosis code was queried to form a de-identified aggregate dataset focused on United States patients: TriNetX is a global research network covering 68 US hospital systems. The NMOSD diagnosis dates range from 1992 to 2022. To increase specificity, patients with less than three NMOSD ICD-10-CM (G36.0) codes were excluded.

Results We identified 2350 unique patients who met the inclusion criteria for further analysis. Of this population 1806 (76.9%) were female, median age was 50.75y [3 – 91], 51.3% were white, 30.4% were black, 3.4% were Asian, and 14.4% were unknown. 1437 (61.15%) patients had recorded symptom ICD-10-CM codes pre-NMOSD diagnosis, 1618 (68.85%) had recorded symptoms post-diagnosis, and 1170 (49.79%) had recorded symptoms pre- and post-diagnosis. For pre- and/or post-NMOSD diagnosis, 965 patients had a recorded optic neuritis diagnosis, 801 had bladder/bowel dysfunction, 771 had muscle weakness, 612 had loss of sensation, 577 had myelitis, 541 had nausea/vomiting/hiccups, 430 had fatigue, 45 had neurogenic pain. Further the following symptoms were recorded pre- and post-NMOSD diagnosis: 517 of 965 (53.58%) patients had optic neuritis, 273 (47.41%) had myelitis, 244 (31.65%) had muscle weakness, 286 (35.71%) had bladder/bowel dysfunction, 126 (23.29%) had nausea/vomiting/hiccups, 132 (21.57%) had loss of sensation, 83 (19.3%) had fatigue, and 4 (8.89%) had neurogenic pain.

Conclusions

The TrinetX database provides an important resource to understand major symptom frequencies in NMOSD prior to formal diagnosis and longitudinally post diagnosis. Future studies can provide insight into the full spectrum of NMOSD symptoms and clinical outcomes.

Authors/Disclosures
Abigail H. Sorenson PRESENTER	Ms. Sorenson has nothing to disclose.
Esther Zeng	Miss Zeng has nothing to disclose.
Tammy L. Smith, MD, PhD (Imaging and Neurosciences Center)	Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. Smith has received research support from Alexion/AstraZeneca.
Melissa A. Wright, MD (University of Utah)	Dr. Wright has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis .
Aditi Sharma (University of Utah)	No disclosure on file
Trieste Francis	Miss Francis has nothing to disclose.
John W. Rose, MD, FAAN (Imaging and Neurosciences Center)	The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.
Ka-Ho Wong (U of U Neurology Clinic)	The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Stacey Clardy, MD, PhD, FAAN (University of Utah)	Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca/Alexion. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Clardy has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/AAN Publications. The institution of Dr. Clardy has received research support from NIH/NINDS. The institution of Dr. Clardy has received research support from SRNA. The institution of Dr. Clardy has received research support from Alexion/AstraZeneca. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a AAN Summer Meeting CoDirector Travel and Lodging with AAN. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a Grand Rounds Travel/Lodging/Honoraria with U of Iowa, Miami, Stanford, Barrow, Beaumont Health, CCF, Emory, Penn State, Mayo Clinic, Walter Reed.

��ɫ��

��ɫ��